Aerie Pharma (AERI) PT Raised to $50 at Cantor Fitzgerald

September 15, 2016 11:42 AM EDT
Get Alerts AERI Hot Sheet
Price: $40.65 --0%

Rating Summary:
    10 Buy, 0 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 18 | Down: 13 | New: 9
Trade AERI Now!
Join SI Premium – FREE

Get access to the best calls on Wall Street with's Ratings Insider Elite. Get your Free Trial here.

Cantor Fitzgerald analyst Elemer Piros reiterated a Buy rating and raised his price target on Aerie Pharma (NASDAQ: AERI) to 50.00 (from $44.00) after the company reported "impeccable" Phase 3 results with its combination eye drop Roclatan from a 700-patient+ trial.

Piros commented, "When comparing the Phase 3 results with an earlier, smaller trial, the combination drug worked even better than its ingredients. Intraocular pressure (IOP) was reduced, on average to 15-16mmHg at all nine time points measured over a 90-day period. The lowering was 1-3mmHg higher than observed with the components, latanoprost and Rhopressa. The difference, as disclosed in a slide deck presented, but not in the press release, was statistically significant with a p value of <0.0001 - very robust. The responder analysis revealed that nearly half of Roclatan-treated patients (46%) experienced a very significant >=35% reduction in IOP. Furthermore, one-third achieved IOP levels at or below 14mmHg, while nearly two-thirds (61%) had pressure that was at or below 16mmHg at day 90."

For an analyst ratings summary and ratings history on Aerie Pharma click here. For more ratings news on Aerie Pharma click here.

Shares of Aerie Pharma closed at $21.13 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change

Related Entities

Cantor Fitzgerald

Add Your Comment